Emerging from the COVID-19 pandemic, pharmaceutical and biotech leaders face acute challenges related to patient recruitment, talent shortages, and the increasing complexity of clinical trials.
The report, R&D Trends in Pharma and Biotech, reflects today’s challenges and opportunities in bringing new therapies to market, as disclosed by more than 150 decision-making leaders at pharmaceutical and biotech companies around the world. Conducted by pharmaceutical market research firm Industry Standard Research (ISR), the survey asked respondents to consider the therapies in their pipelines, barriers to drug development, latest innovations in use, and the lingering effects and lessons of the COVID-19 pandemic.
Read more about the report and how to download it here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.